Ion Beam Applications SA ( IBAB.BR) Stock. Should you Buy or Sell? $ 15.66
-0.36 (-2.35 %)
Ion Beam Applications SA Analysis
Updated on 10-09-2022
| Symbol |
IBAB.BR |
| Price |
$15.66 |
| Beta |
0.633 |
| Volume Avg. |
$11.84 thousand |
| Market Cap |
$461.4 M |
| 52 Week Range |
$13.62 - $20.45 |
Ion Beam Applications SA opened the day at $15.66 which is -2.35 % on yesterday's close.
Ion Beam Applications SA has a 52 week high of $20.45 and 52 week low of $13.62, which is a difference of $6.83.
We like to see positive, upward trending shares, preferably with momentum.
Market capitalization is $461.4 M and total net profit is $312964000 which means the company is trading at 1.47 times profit to market capitalization. Theoretically, if you were to buy Ion Beam Applications SA for $461.4 M, it would take 15 years to get your money back. Ion Beam Applications SA are in the Medical Devices space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
1 D | All
Financials
Ion Beam Applications SA Stock Forecast - Is Ion Beam Applications SA a Buy or Sell?
| DCF Score | | Strong Buy |
| ROE Score | | Neutral |
| ROA Score | | Neutral |
| DE Score | | Strong Buy |
| PE Score | | Strong Buy |
| PB Score | | Strong Buy |
| Overall Recommendation | | Strong Buy |
Growth and Value
| PE Ratio |
120.462 |
| Dividend Yiel |
0.012 |
| Net Profit Margin |
0.017 |
Valuing Ion Beam Applications SA
| Price Book Value Ratio |
4.742 |
Price To Book Ratio |
4.742 |
| Price To Sales Ratio |
1.747 |
Price Earnings Ratio |
100.097 |
How liquid is Ion Beam Applications SA
| Current Ratio |
1.119 |
| Quick Ratio |
0.507 |
Debt
| Debt Ratio |
0.823 |
Debt Equity Ratio |
4.656 |
| Long Term Debt To Capitalization |
0.336 |
Total Debt To Capitalization |
0.400 |
Latest news about Ion Beam Applications SA
About Ion Beam Applications SA
CEO : Mr. Olivier Legrain
Sector : Healthcare
Industry : Medical Devices
Website : https://www.iba-worldwide.com
Description :
Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for advance research in ConformalFLASH. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.
